Conventional tumour markers such as CEA and alpha-fetoprotein are used to monitor treatment and detect recurrence'`of malignancy. These tumour markers also show a non-specific reactivity in benign diseases' and sometimes in even normal individuals.6À ttempts have been made to search for monoclonal antibodies which might be used as tumour markers. CA 19-9, an antigenic determinant defined by murine monoclonal antibody 1116NS19-9, was generated by somatic hybridisation of the mouse myeloma cell line and splenocytes from a mouse
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